NCT02338921View on ClinicalTrials.gov

Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

November 30, 2021

Study Completion Date

December 31, 2021

Conditions
Type 2 Diabetes
Interventions
DRUG

Sitagliptin

"100mg qd per oral during 24months~compared with other treatment groups"

DRUG

Dapagliflozin

"10mg qd per oral during 24months~compared with other treatment groups"

DRUG

Lobeglitazone

"0.5mg qd per oral during 24months~compared with other treatment groups"

DRUG

Glimepirde

DRUG

Metformin

Trial Locations (1)

463-707

Soo Lim, Seongnam-si

All Listed Sponsors
lead

Seoul National University Bundang Hospital

OTHER

NCT02338921 - Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy | Biotech Hunter | Biotech Hunter